Sovaldi

GPTKB entity

Statements (58)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:approves gptkb:FDA
gptkbp:availability prescription only
gptkbp:brand gptkb:sofosbuvir
gptkbp:can_be_combined_with gptkb:ledipasvir
gptkb:ribavirin
gptkbp:class antiviral
gptkbp:clinical_trial Phase 3
gptkbp:clinical_use chronic hepatitis C genotype 1, 2, 3, 4, 5, 6
gptkbp:contraindication severe liver disease
gptkbp:dosage_form gptkb:tablet
gptkbp:drug_interactions gptkb:phenytoin
gptkb:St._John's_Wort
gptkb:carbamazepine
gptkb:amiodarone
gptkb:rifampin
gptkbp:duration 12 weeks
24 weeks for certain genotypes
gptkbp:events monitoring liver function
HCV RNA testing
gptkbp:financial_support financial assistance programs
available through manufacturer
gptkbp:formulation sofosbuvir 400 mg tablet
gptkbp:global_access available in many countries
affordable generics in some regions
https://www.w3.org/2000/01/rdf-schema#label Sovaldi
gptkbp:ingredients gptkb:sofosbuvir
gptkbp:invention 2028
gptkbp:manufacturer gptkb:Gilead_Sciences
gptkbp:marketed_as gptkb:2013
gptkbp:mechanism_of_action NS5 B polymerase inhibitor
gptkbp:patient_education potential side effects
importance of adherence
gptkbp:patient_population adults
pediatric patients
gptkbp:price approximately $84,000 for a 12-week treatment
gptkbp:provides_guidance_on recommended by AASLD
recommended by EASL
gptkbp:regulatory_compliance gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkbp:research_focus resistance testing
treatment of co-infections
long-term outcomes of treatment
new combinations with other antivirals
gptkbp:route_of_administration oral
gptkbp:side_effect gptkb:anemia
fatigue
headache
hydration
nausea
insomnia
antiemetics
gptkbp:storage room temperature
gptkbp:success_rate over 90% for certain genotypes
gptkbp:treatment chronic hepatitis C
gptkbp:used_for treatment of hepatitis C
gptkbp:bfsParent gptkb:Gilead_Sciences
gptkbp:bfsLayer 4